HLVX Insider Report: Merger Pays $1.95 per Share Plus CVR; RSUs Settled
Rhea-AI Filing Summary
Aditya Kohli, a director of HilleVax, Inc. (HLVX), reported on Form 4 a transaction dated 09/17/2025 showing 698,171 shares of Common Stock disposed in connection with a completed merger. The filing explains that XOMA Royalty Corporation completed a tender offer and Merger Sub merged into HilleVax under a Merger Agreement dated August 4, 2025. Consideration to former shareholders consisted of $1.95 in cash per share plus one contingent value right (CVR) per share to receive certain contingent cash payments. The filing also states that outstanding restricted stock units vested and were canceled for cash equal to the cash amount times underlying shares plus one CVR per share. The Form 4 was signed by an attorney-in-fact for Mr. Kohli.
Positive
- Acquisition completed by XOMA Royalty Corporation converting public equity into cash and contingent rights
- Cash consideration specified at $1.95 per share providing immediate liquidity to shareholders
- RSUs fully vested and settled for cash plus CVRs, ensuring award holders received the same consideration
Negative
- Reported disposition of 698,171 shares by the reporting person resulting in reported direct ownership of 0 shares
- Future upside contingent on CVR payments rather than ongoing equity exposure in HilleVax
Insights
TL;DR Insider disposed all reported holdings due to a merger that paid $1.95 per share plus a CVR, converting equity into cash and contingent rights.
This Form 4 documents a corporate ownership change driven by a completed acquisition structure: a tender offer followed by a merger making HilleVax a wholly owned subsidiary of XOMA Royalty Corporation. The cash consideration of $1.95 per share plus CVRs converts equity value into immediate cash and potential contingent payments, removing the reported insider's direct shareholdings (698,171 shares disposed). For analysts, the key takeaways are the fixed cash consideration, the presence of CVRs which retain contingent upside, and the full vesting and cancellation treatment for RSUs ensuring holders received equivalent cash and CVR treatment.
TL;DR Transaction reflects standard M&A settlement mechanics: tender offer, merger, accelerated RSU vesting, and Form 4 reporting of resulting dispositions.
The filing shows appropriate disclosure of insider dispositions tied to the Merger Agreement dated August 4, 2025 and the Effective Time of September 17, 2025. Accelerated vesting of RSUs and cash+CVR treatment is explicitly described, which is common in control transactions to equitably settle equity awards. The Form 4 indicates compliance with Section 16 reporting via attorney-in-fact signature. Governance specialists would note the transaction removes reported public insider holdings and replaces share exposure with contractual CVR arrangements that may have specific governance and claim priorities outlined in a separate CVR Agreement.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| U | Common Stock | 698,171 | $0.00 | -- |
Footnotes (1)
- In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.
